Loading...
HLVX HilleVax
No Data
News
Comment
76 Biggest Movers From Yesterday
Gainers Bright Green Corp. (NASDAQ:BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to li
90 Biggest Movers From Yesterday
Losers Akanda Corp. (NASDAQ:AKAN) dipped 74.3% to close at $2.29.Party City Holdco Inc. (NYSE:PRTY) shares tumbled 61.4% to close at $1.18 on Monday after the company reported worse-than-expected Q1
Executives Buy Around $85M Of 4 Stocks
Although crude oil futures traded higher on Wednesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they vie
HilleVax: Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shrs
HilleVax: Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shrs
HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
BOSTON, May 03, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the closing of its initial public offering of 13,529,750 shares
HilleVax initiates Phase 2b trial of HIL-214 vaccine candidate
HilleVax reported dosing of the first subjects in its previously announced Phase 2b clinical trial of HIL-214, the company's virus-like particle based vaccine candidate, for the prevention of moderate
HilleVax Announces Initiation Of Phase 2b Clinical Trial Of HIL-214 Vaccine Candidate For The Prevention Of Norovirus-Related Acute Gastroenteritis In Infants
HilleVax, Inc. (NASDAQ:HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously an
HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
BOSTON, May 02, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a biopharmaceutical company focused on the development and commercialization of novel vaccine candidates, reported today dosing of the first subjects in its previously announced Pha
Opening Day: Tenon Medical shares soar in market debut
Shares of Tenon Medical soared in their market debut on Wednesday, opening at $22.05 after the medical-device company had priced its IPO at $5 per share. LATEST IPOS AND DIRECT LISTINGS: Belite Bio (B
Norovirus vaccine developer HilleVax stock climbs 10% following upsized $200M IPO
Norovirus vaccine developer HilleVax (HLVX) shares rose 10% following its upsized $200M initial public offering. Shares of HLVX opened at $18.76 after pricing at $17 per share. The stock recently cha